Institutional investors purchased a net $2.0 million shares of MACK during the quarter ended September 2014. This may signal that the smart money is gaining interest in this company as the 52.39% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BOSTON PRIVATE BANK & TRUST CO. Bought 68.4 Thousand shares of Merrimack Pharmaceuticals...